Hepatitis B surface antigen prevalence in pregnant women before and after national vaccinations
- Authors: Hedayati F.1, Lotfi S.1, Ebrahimi P.1, Javanian M.1, Bayani F.1, Darbandi Z.1, Bayani M.1
-
Affiliations:
- Babol University of Medical Sciences
- Issue: Vol 15, No 3 (2025)
- Pages: 587-591
- Section: SHORT COMMUNICATIONS
- URL: https://bakhtiniada.ru/2220-7619/article/view/315142
- DOI: https://doi.org/10.15789/2220-7619-HBS-15617
- ID: 315142
Cite item
Full Text
Abstract
Background. Hepatitis B in pregnant mothers can pose a risk to both the mother and the baby. If left untreated or undiagnosed, hepatitis B can be passed from mother to child during childbirth, leading to chronic hepatitis B infection in the baby. However, with proper prenatal care, including testing and vaccination, the risk of transmission can be significantly reduced. This study investigates the hepatitis B surface antigen (HBsAg) prevalence in pregnant women before and after the start of the national hepatitis B vaccination plan. Materials and methods. This cross-sectional study was conducted on all pregnant mothers in Babol County who gave birth between 2018 and 2020. Then the mothers’ information, including a history of vaccination, place of residence, and HBsAg status, was recorded and checked through the online system and their health records. The obtained data were analyzed using SPSS software version 22 and were displayed as frequency and percentage. Qualitative variables were analyzed with Chi-square tests. Finally, with the logistic regression model, we investigated the effect of variables on hepatitis. In all tests, P-value less than 0.05 is significant. Results. The prevalence of positive HBsAg among 11 282 pregnant women in Babol city was 61 (0.5%). The prevalence rate among vaccinated and unvaccinated mothers was 8 (0.2%) and 53 (0.7%), respectively, and this difference was statistically significant (p = 0.001). The Prevalence of positive HBsAg among city and village residents was 26 people (0.4%) and 35 people (0.7%), respectively, and this difference was not significant (p = 0.07). Also, rural (p = 0.02, OR = 1.82, 95%CI: 1.08–302) and unvaccinated (p < 0.001, OR = 3.79, 95%CI: 1.79–8.01) mothers had a higher chance of contracting hepatitis B. Conclusion. The results indicated that national hepatitis B vaccination in newborns has notably decreased infection rates in future childbearing women. Hepatitis B is a preventable disease through vaccination. The vaccine has demonstrated both safety and high immunogenicity. It is crucial to maintain the immunization of newborns and adhere to the screening guidelines for pregnant mothers as outlined in the national program.
Full Text
##article.viewOnOriginalSite##About the authors
Faeghe Hedayati
Babol University of Medical Sciences
Email: Faeghe.hedayati@yahoo.com
Student Research Committee
Iran, Islamic Republic of, BabolSam Lotfi
Babol University of Medical Sciences
Email: sam.lotfiii@outlook.com
Student Research Committee
Iran, Islamic Republic of, BabolPouyan Ebrahimi
Babol University of Medical Sciences
Email: pouyanebi1375@gmail.com
Student Research Committee
Iran, Islamic Republic of, BabolMostafa Javanian
Babol University of Medical Sciences
Email: mjavanian@gmail.com
Associate Professor of Infectious Disease, Infectious Diseases and Tropical Medicine Research Center, Health Research Institute
Iran, Islamic Republic of, BabolFatemeh Bayani
Babol University of Medical Sciences
Email: monirehbayani@yahoo.com
General Doctor (MPH), Health Vice-Chancellor
Iran, Islamic Republic of, BabolZeinab Darbandi
Babol University of Medical Sciences
Email: zeinabdarbandi@yahoo.com
Student Research Committee
Iran, Islamic Republic of, BabolMasomeh Bayani
Babol University of Medical Sciences
Author for correspondence.
Email: rohanresearch88@gmail.com
Professor of Infectious Disease, Infectious Diseases and Tropical Medicine Research Center, Health Research Institute
Iran, Islamic Republic of, BabolReferences
- Alimonos K., Nafziger A.N., Murray J., Bertino J.S. Jr. Prediction of response to hepatitis B vaccine in health care workers: whose titers of antibody to hepatitis B surface antigen should be determined after a three-dose series, and what are the implications in terms of cost-effectiveness? Clin. Infect. Dis., 1998, vol. 26, no. 3, pp. 566–571. doi: 10.1086/514575
- Amini S., Andalibi Mahmoudabadi S., Taghavinejad F., Joulaie M., Farahani M., Hekmat S. Transplacental Transmission of Hepatitis B Virus in Mazandaran Province of Iran. Iran. J. Virol., 2008, vol. 2, no. 3–4, pp. 14–18.
- Badfar G., Shohani M., Nasirkandy M.P., Mansouri A., Abangah G., Rahmati S., Azami M., Soleymani A., Mohammadi M., Gholami F., Mahmoudi L., Khatony A. Epidemiology of hepatitis B in pregnant Iranian women: a systematic review and meta-analysis. Arch. Virol., 2018, vol. 163, no. 2, pp. 319–330. doi: 10.1007/s00705-017-3551-6
- Batayneh N., Bdour S. Risk of perinatal transmission of hepatitis B virus in Jordan. Infect. Dis. Obstet. Gynecol., 2002, vol. 10, no. 3, pp. 127–132. doi: 10.1155/S1064744902000121
- Bayani M., Biazar T., Hasanjani R.M., Bayani F., Siadati S. The effect of hepatitis B vaccination at birth on reducing the prevalence of hepatitis B surface antigen among rural pregnant women in Babol, Iran. N. U. Monthly, 2016. doi: 10.5812/numonthly.37878
- Herman A., Bullen C., Finau S., Ofanoa M. Mobilising Pacific people for health: insights from a hepatitis B screening program in Auckland, New Zealand. Pac. Health Dialog., 2006, vol. 13, no. 2, pp. 9–15.
- Jafarzadeh A., Khoshnoodi J., Ghorbani S., Mohaghegh Hazrati S., Faraj Mazaheri B., Shokri F. Differential Immunogenicity of A Recombinant Hepatitis B Vaccine in Iranian Neonates: Influence of Ethnicity and Environmental Factors. Iran. J. Immunol., 2004, vol. 1, no. 2, pp. 98–104.
- Klinger G., Chodick G., Levy I. Long-term immunity to hepatitis B following vaccination in infancy: Real-world data analysis. Vaccine, 2018, vol. 36, no. 17, pp. 2288–2292. doi: 10.1016/j.vaccine.2018.03.028
- Koike Y., Yoo Y.C., Mitobe M., Oka T., Okuma K., Tono-oka S., Saito S., Sato K., Sato S., Sato Y. Enhancing the activity of mycobacterial cell-derived adjuvants on the immunogenicity of recombinant human hepatitis B virus vaccine. Vaccine, 1998, vol. 16, no. 20, pp. 1982–1989. doi: 10.1016/s0264-410x(98)00084-x
- Merat S., Rezvan H., Nouraie M., Jamali J., Assari S., Abolghasemi H., Pourshams A., Malekzadeh R. The prevalence of hepatitis B surface antigen and anti-hepatitis B core antibody in Iran: a population-based study. Arch. Iran. Med., 2009, vol. 12, no. 3, pp. 225–231.
- Milich D.R., Leroux-Roels G.G. Immunogenetics of the response to HBsAg vaccination. Autoimmun. Rev., 2003, vol. 2, no. 5, pp. 248–257. doi: 10.1016/s1568-9972(03)00031-4
- Mohammadi Z., Keshtkar A., Eghtesad S., Jeddian A., Pourfatholah A.A., Maghsudlu M., Amini Kafi-Abad S., Abolghasemi H. Epidemiological profile of hepatitis B virus infection in Iran in the past 25 years; a systematic review and meta-analysis of general population studies. Middle East J. Dig. Dis., 2016, vol. 8, no. 1, pp. 5–18. doi: 10.15171/mejdd.2016.01
- Rezaee R., Aghcheli B., Poortahmasebi V., Qorbani M., Alavian S.M., Jazayeri S.M. Prevalence of national responsiveness to HBV vaccine after 22 years of Iranian expanded program on immunization (EPI): a systematic review and meta-analysis study. Hepat. Mon., 2015, vol. 15, no. 5: e23618. doi: 10.5812/hepatmon.15(04)2015.23618
- Saffar H., Ajami A., Saffar M.J., Shojaei J., Sotudeh-Anvari M., Shams-Esfandabad K., Khalilian A.R., Saffar M.J. Prevalence of hepatitis B virus ser o markers in young adults vaccinated at birth; impact on the epidemiology of hepatitis B infection in Iran. Hepat. Mon., 2014, vol. 14, no. 5: e17263. doi: 10.5812/hepatmon.17263
- Salehi-Vaziri M., Sadeghi F., Hashiani A.A., Fesharaki M.G., Alavian S.M. Hepatitis B virus infection in the general population of Iran: an updated systematic review and meta-analysis. Hepat. Mon., 2016, vol. 16, no. 4: e35577. doi: 10.5812/hepatmon.35577
- Shoghli A., Nabavi S.M., Alavian S.M., Kolifarhood G., Goya M.M., Namazi R., Sharifi H., Eshrati B., Haghdoost A.A. Hepatitis B surface antigen prevalence in pregnant women: a cross-sectional survey in Iran. Int. J. Prev. Med., 2014, vol. 5, suppl. 3, pp. S213–S217.
- Somi M.H., Khayatzadeh S., Nalbandy M., Naghashi S., Nikniaz Z. Estimating the incidence rate of hepatitis B and C in East Azerbaijan, Islamic Republic of Iran. East. Mediterr. Health J., 2020, vol. 26, no. 7, pp. 803–809. doi: 10.26719/emhj.19.077
- Tazhibi M., Hajivandi A., Tafti A.D., Fallahzadeh H. The efficacy of hepatitis B vaccine in Iranian population: a systematic review and meta-analysis. J. Educ. Health Promot., 2014, vol. 3: 53. doi: 10.4103/2277-9531.134741
- Tsankova G.S., Kostadinova T., Todorova T.T. Seroprevalence of Hepatitis B among pregnant women in Varna Region, Bulgaria. J. Med. Virol., 2016, vol. 11, no. 88, pp. 2012–2018. doi: 10.1002/jmv.24543
- Wang F., Kang W., Zhou W., Su Q., Bi S., Qiu F., Li Q. Investigation of the risk factors associated with the failure of hepatitis B vaccination of neonates in Yunnan province, China. Int. J. Infect. Dis., 2018, vol. 77, pp. 90–95. doi: 10.1016/j.ijid.2018.09.026
- WHO. Hepatitis B [Internet] 2020 [cited 2020 Nov 2]. URL: https://www.who.int/news-room/fact-sheets/detail/hepatitis-b
- WHO. Hepatitis B [Internet] 2022 [cited 2022 July 27]. URL: https://www.who.int/news-room/fact-sheets/detail/hepatitis-b
Supplementary files
